Sales grew faster in the third quarter than had been anticipated in the Company’s previous statements regarding sales for the remainder of 2006. It is expected that fourth quarter sales growth will be slower, when compared to the fourth quarter of 2005, than the growth that the Company experienced in the first nine months of 2006. Although the sales order backlog is strong, the Company continues to be cautious regarding the effect of some order acceleration in the first half of the year on fourth quarter sales, and the potential for the further impact of customers’ inventory management measures on orders and delivery dates around the end of the calendar year.

The cost of the Company’s primary raw materials (synthetic rubber, plastic resins and rolled aluminum), as well as other oil and energy-related material and overhead costs did adversely impact results in the third quarter in the Pharmaceutical Systems segment. Because of contractual commitments, those increases are expected to persist in the fourth quarter despite the recent trend toward lower commodity prices. The Company continues to expect that, for the full year, the contribution from its pricing, cost control and lean manufacturing efforts will equal or exceed material and energy cost increases. Higher spending on product innovation projects is also expected to continue through the remainder of the year.

The Company is pleased to note that the situation in northern Israel has stabilized and it has not had, and is not expected to have, an impact on customer deliveries or financial results in the acquired Medimop Medical Projects business.

The Company is further accelerating the expansion of its production capacity. Incremental spending is focused on expansions in the Company’s European and Asia/Pacific operating regions. More specifically, several agreements have been concluded relating to the establishment of production facilities in China, with completion and initial production planned for 2009. Current expectations are that 2006 capital spending will be between $80 and $90 million, as some of the earlier-announced 2006 spending will now occur in 2007, contributing to the higher spending plans for next year, now estimated to be between $110 and $125 million.

The Company will host its regular quarterly earnings release and analyst call, which is scheduled for 9 a.m. eastern daylight time on November 2, 2006. To participate in the call please dial (888) 843-9981 or (210) 234-0014, passcode: WST. A live web cast will be available along with an online archive of the broadcast that will be available within two hours of the live call and will remain on the Company’s web site until the next quarterly conference call. Listeners may also access a telephone replay of the conference call, available through Friday, November 17, 2006, by dialing (866) 416-1174 or (203) 369-0714.

West Pharmaceutical Services, Inc. is the world's premier manufacturer of components and systems for injectable drug delivery, including stoppers and seals for vials, and closures and

disposable components used in syringe, IV and blood collection systems. The Company also provides products with application to the personal care, food and beverage markets. West's customers include the world's leading pharmaceutical, biotechnology, generic drug and medical device producers. Headquartered in Lionville, Pennsylvania, West Pharmaceutical Services supports its partners and customers from 50 locations throughout North America, South America, Europe, Mexico, Japan, Asia and Australia. For more information, visit West at http://www.westpharma.com.

Cautionary Statement Regarding Forward-Looking Information

This press release contains some forward-looking statements that set forth anticipated results based on management’s plans and assumptions. Such statements give our current expectations or forecasts of future events – they do not relate strictly to historical or current facts. In particular, these include statements concerning future actions, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings and financial results. We have tried, wherever possible, to identify such statements by using words such as “estimate,” “expect,” “intend,” “believe,” “plan,” “anticipate” and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or condition.

We cannot guarantee that any forward-looking statement will be realized. If known or unknown risks or uncertainties materialize, or if underlying assumptions are inaccurate, actual results could differ materially from past results and those expressed or implied in any forward-looking statement. You should bear this in mind as you consider forward-looking statements. We cannot predict or identify all such risks and uncertainties, but factors that could cause the actual results to differ materially from expected and historical results include the following: sales demand; the timing, regulatory approval and commercial success of customers’ products incorporating our products and services, including specifically, the Exubera® Inhalation-Powder insulin device; customers’ changes to inventory requirements and manufacturing plans that alter existing orders or ordering patterns for our products; our ability to pass raw-material cost increases on to customers through price increases; maintaining or improving production efficiencies and overhead absorption; physical limits on manufacturing capacity that may limit our ability to satisfy anticipated demand; the availability of labor to meet increased demand; competition from other providers; average profitability, or mix, of products sold in a reporting period; financial performance of unconsolidated affiliates; strength of the U.S. dollar in relation to other currencies, particularly the Euro, UK Pound, Danish Krone, Japanese Yen and Singapore Dollar; higher interest rates; interruptions or weaknesses in our supply chain, which could cause delivery delays or restrict the availability of raw materials and key bought-in components and finished products, including products produced in northern Israel; raw-material price escalation, particularly petroleum-based raw materials, and energy costs; availability, and pricing of materials that may be affected by vendor concerns with exposure to product-related liability; and, changes in tax law or loss of beneficial tax incentives.

We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.

Westar®, Flip-Off® and FluroTec® are registered trademarks of West Pharmaceutical Services, Inc.

Exubera® is a registered trademark of Pfizer Inc.

Teflon® is a registered trademark of E.I. du Pont de Nemours and Company

WEST PHARMACEUTICAL SERVICES, INC.

CONSOLIDATED STATEMENTS OF INCOME

(in thousands, except per share data)

	Three Months Ended												Nine Months Ended
				September 30, 2006					September 30, 2005				September 30, 2006		September 30, 2005
Net sales	$	218,400		100	%	$	181,600		100	%	$	681,400	100	%	$	504,000		100	%
Cost of goods sold		159,600		73			137,800		76			485,200	71			363,200		72
Gross profit		58,800		27			43,800		24			196,200	29			140,800		28
Selling, general and administrative expenses		37,100		17			30,700		17			112,000	16			87,900		17
Restructuring credit		—		—			(100	)	—			—	—			(1,500	)	—
Other expense, net		2,000		1			—		—			4,200	1			1,200		—
Operating profit		19,700		9			13,200		7			80,000	12			53,200		11
Loss on debt extinguishment		—		—			—		—			5,900	1			—		—
Interest expense, net		2,700		1			3,700		2			8,500	1			8,500		2
Income before income taxes		17,000		8			9,500		5			65,600	10			44,700		9
Provision for income taxes		4,900		2			3,000		2			19,400	3			14,200		3
Minority interests		100		—			—		—			300	—			—		—
Income from consolidated operations		12,000		6	%		6,500		3	%		45,900	7	%		30,500		6	%
Equity in net income of affiliated companies		(200	)				600					900				1,900
Income from continuing operations		11,800					7,100					46,800				32,400
Discontinued operations, net of tax		1,500					700					5,300				1,500
Net income	$	13,300				$	7,800				$	52,100			$	33,900

Net income per share:
Basic:
Continuing operations	$	0.37	$	0.23	$	1.46	$	1.05
Discontinued operations		0.04		0.02		0.17		0.05
	$	0.41	$	0.25	$	1.63	$	1.10
Assuming dilution:
Continuing operations	$	0.35	$	0.22	$	1.39	$	1.00
Discontinued operations		0.04		0.02		0.16		0.05
	$	0.39	$	0.24	$	1.55	$	1.05
Average common shares outstanding		32,232		31,334		32,023		30,988
Average shares assuming dilution		33,829		32,776		33,584		32,401

WEST PHARMACEUTICAL SERVICES

REPORTING SEGMENT INFORMATION

(in thousands)

	Three Months Ended						Nine Months Ended
	September 30						September 30
Net Sales:	2006			2005			2006			2005
Pharmaceutical Systems	$	153,700		$	127,400		$	480,100		$	401,800
Tech Group		66,900			56,100			209,100			108,600
Eliminations		(2,200	)		(1,900	)		(7,800	)		(6,400	)
Consolidated Total	$	218,400		$	181,600		$	681,400		$	504,000

Operating Profit (Loss):
Pharmaceutical Systems	$	26,600		$	18,800		$	100,400		$	71,800
Tech Group		3,500			2,100			13,100			5,900
Restructuring Credit		—			100			—			1,500
Corporate costs		(6,100	)		(4,500	)		(17,700	)		(14,600	)
Stock based compensation costs		(2,500	)		(2,000	)		(9,400	)		(7,600	)
Domestic pension expense		(1,800	)		(1,300	)		(6,400	)		(3,800	)
Consolidated Total	$	19,700		$	13,200		$	80,000		$	53,200

WEST PHARMACEUTICAL SERVICES

REPORTING SEGMENT COMPARISON (UNAUDITED)

THREE MONTHS ENDED SEPTEMBER 30, 2006

(in millions)

													(Including Acquisitions)						(Excluding Acquisitions)
	Pharmaceutical Systems						Tech Group						Consolidated						Consolidated
	Q3 2006			Q3 2005			Q3 2006			Q3 2005			Q32006			Q3 2005			Q32006			Q3 2005
Net Sales	$	153.7		$	127.4		$	66.9		$	56.1		$	218.4		$	181.6		$	163.0		$	140.0
Growth %		20.6	%					19.3	%					20.3	%					16.5	%

Gross Profit	$	50.0		$	36.9		$	8.8		$	6.9		$	58.8		$	43.8		$	49.9		$	38.5
Gross Margin %		32.6	%		29.0	%		13.1	%		12.4	%		26.9	%		24.1	%		30.6	%		27.5	%

Operating Profit	$	26.6		$	18.8		$	3.5		$	2.1		$	19.7		$	13.2		$	15.7		$	12.0
Operating Margin %		17.3	%		14.8	%		5.2	%		3.6	%		9.0	%		7.2	%		9.7	%		8.5	%

WEST PHARMACEUTICAL SERVICES

REPORTING SEGMENT COMPARISON (UNAUDITED)

NINE MONTHS ENDED SEPTEMBER 30, 2006

(in millions)

													(Including Acquisitions)						(Excluding Acquisitions)
	Pharmaceutical Systems						Tech Group						Consolidated						Consolidated
	YTD 2006			YTD 2005			YTD 2006			YTD 2005			YTD2006			YTD 2005			YTD2006			YTD 2005
Net Sales	$	480.1		$	401.8		$	209.1		$	108.6		$	681.4		$	504.0		$	512.1		$	443.6
Growth %		19.5	%					92.5	%					35.2	%					15.4	%

Gross Profit	$	166.6		$	125.8		$	29.6		$	15.0		$	196.2		$	140.8		$	168.5		$	132.5
Gross Margin %		34.7	%		31.3	%		14.2	%		13.8	%		28.8	%		27.9	%		32.9	%		29.9	%

Operating Profit	$	100.4		$	71.8		$	13.1		$	5.9		$	80.0		$	53.2		$	67.3		$	50.4
Operating Margin %		20.9	%		17.9	%		6.3	%		5.4	%		11.7	%		10.5	%		13.2	%		11.4	%

WEST PHARMACEUTICAL SERVICES

NON-GAAP MEASURES (UNAUDITED)

NINE MONTHS ENDED SEPTEMBER 30, 2006

(in thousands, except per share data)

	As Reported Sept. 30, 2006		Extinguishment of Debt			Tax Settlement			Non-GAAP Sept. 30, 2006
Operating profit	$	80,000	$	—		$	—		$	80,000
Loss on debt extinguishment		5,900		(5,900	)		—			—
Interest expense, net		8,500		—			300			8,800
Income before income taxes		65,600		5,900			(300	)		71,200
Provision for income taxes		19,400		1,800			400			21,600
Minority interests		300		—			—			300
Income from consolidated operations		45,900		4,100			(700	)		49,300
Equity in net income of affiliated companies		900		—			—			900
Income from continuing operations	$	46,800	$	4,100		$	(700	)	$	50,200

Net income per diluted share:
Continuing operations	$	1.39	$	0.12		$	(0.02	)	$	1.50

Earnings per share figures do not add across due to rounding.

The Company incurred a $5,900 pre-tax charge in connection with the refinancing of $100 million of debt obligations and recognized a tax benefit of $400 as a result of the conclusion of a claim for an earlier tax period. Interest income of $300 was recorded on the tax benefit received.

The above items occurred in the first quarter of 2006 and have no impact on third quarter results.

These items represent non-GAAP financial measures used by management to assess financial performance. Non-GAAP financial measures are intended to explain or aid in the use of, not as a substitute for, the related GAAP financial measures.